Glaxo Wellcome/Warner-Lambert's Zantac 75 clears FDA advisory committee July 13.
This article was originally published in The Tan Sheet
Executive Summary
ZANTAC 75 RECEIVES UNANIMOUS RECOMMENDATION FOR OTC APPROVAL at a joint meeting of the Nonprescription Drugs and Gastrointestinal Drugs Advisory Committees on July 13. Glaxo Wellcome's Zantac 75 (ranitidine HCl) is expected to be the third H2 antagonist approved by FDA this year, following J&J/Merck's Pepcid AC and SmithKline Beecham's Tagamet HB.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning